Key result
Ongoing use of aspirin at symptom onset in patients with acute myocardial infarction was associated with an increased likelihood of developing a non-Q-wave myocardial infarction.
Why the study?
Does ongoing use of aspirin reduce infarct size and increase the frequency of non-Q-wave myocardial infarctions in patients with acute myocardial infarction?
Cohort (n=753)
Does ongoing use of aspirin reduce infarct size and increase the frequency of non-Q-wave myocardial infarctions in patients with acute myocardial infarction?
Ongoing aspirin use at the onset of acute myocardial infarction symptoms is associated with a shift toward less severe manifestations, including smaller infarct size and more non-Q-wave infarctions.
Answers are grounded in this paper and cite their sources.
May suggest smaller infarcts with ongoing aspirin in AMI; hypothesis-generating and should not yet change practice.
In an observational study we wanted to investigate whether ongoing use of aspirin in a cohort of 753 patients with acute myocardial infarction was able to (1) reduce infarct size as assessed by peak creatine kinase and lactate dehydrogenase, (2) increase the number of non-Q-wave myocardial infarctions, and (3) to what extent thrombolytic treatment at admission could modify these outcomes. We used an exposed (aspirin+)/nonexposed (aspirin-) cohort design, adjusting for the effects of confounders (age, previous coronary heart disease, current smoking, and the prior use of beta-blockers and long-acting nitrates) as well as for the modifying effect of thrombolytic treatment. Crude and adjusted effects showed that aspirin reduced infarct size only in patients not receiving thrombolytic treatment at admission to hospital (n = 411 patients). In analyzing the occurrence of non-Q-wave versus Q-wave myocardial infarctions, the outcome was dichotomized. Crude odds ratio (OR) for developing a non-Q-wave myocardial infarction in aspirin users was 2. 63 (2p < 0.001), in the restricted cohort of patients receiving thrombolytic treatment, OR was 3.46 (2p = 0.002), whereas in those not receiving such treatment, OR was 1.81 (2p = 0.007). Adjusting for the effects of confounders, retained aspirin was an independent predictor of non-Q-wave myocardial infarctions, an effect that was probably increased (from 51 to 128%) in those who received thrombolytic treatment. Thus, aspirin seems to produce a shift to less severe manifestations of myocardial infarction, an effect that was increased in patients given thrombolytic treatment at admission to hospital.
No takes yet. Share an insight, caveat, or question.
Abdelnoor et al. (1999) conducted a cohort in Acute myocardial infarction (n=753). Ongoing use of aspirin at the onset of symptoms vs. Nonexposed (aspirin-) was evaluated on Developing a non-Q-wave myocardial infarction (OR 2.63, p=<0.001). Ongoing use of aspirin at symptom onset in patients with acute myocardial infarction was associated with an increased likelihood of developing a non-Q-wave myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: